Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
86.16(c) 86.92(c) 85.21(c) 87.16(c) 86.15(c) Last
1 309 558 1 037 735 1 167 409 944 658 875 623 Volume
+0.10% +0.88% -1.97% +2.29% -1.16% Change
More quotes
Financials ($)
Sales 2016 1 114 M
EBIT 2016 -740 M
Net income 2016 -579 M
Finance 2016 108 M
Yield 2016 -
Sales 2017 1 317 M
EBIT 2017 -146 M
Net income 2017 -179 M
Finance 2017 55,9 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 13,2x
EV / Sales2017 11,2x
Capitalization 14 817 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
01/19 BIOMARIN PHARMACEUTICAL : Transfers Duchenne Natural History Database to CureDuc..
01/09 BIOMARIN PHARMACEUTICAL : Research Reports Initiation on Biotech Stocks -- Immun..
01/09 BIOMARIN PHARMACEUTICAL : to Provide Update to Proof-of-Concept Data for BMN 270..
01/03 BIOMARIN PHARMACEUTICAL : to Present at 35th Annual J.P. Morgan Healthcare Confe..
2016 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) Files An 8-K Entry into a Material ..
2016 BIOMARIN PHARMACEUTICAL INC : Entry into a Material Definitive Agreement, Change..
2016 BIOMARIN PHARMACEUTICAL : Torray LLC Sells 169,288 Shares of BioMarin Pharmaceut..
2016 BIOMARIN PHARMACEUTICAL : Enrolls First Participant in Phase 3 Trial of Vosoriti..
2016 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) Files An 8-K Departure of Directors..
2016 BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatme..
More news
Sector news : Biopharmaceuticals
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Biopharmaceuticals
Latest Tweets
01/18$BMRN D1 > 50SMA - tightly wound  
01/18From : With gene therapy closing in on , BioMarin expands in North Bay  
01/17BioMarin Pharmaceutical downgraded by Zacks Investment Research to hold.  
01/17Nice lil' writeup this AM by Yeezus: Trump headlines on 'drug pricing' - shou..
12
01/17From : With gene therapy closing in on , BioMarin expands in North Bay  
More tweets
Qtime:73
News from SeekingAlpha
01/19 Early-stage study data on Catabasis Pharma's Duchenne candidate edasalonexent..
01/11 Allergan CEO also has a Twitter account
01/11 BIOTECH FORUM DAILY DIGEST : Keytruda Continues To Power Merck; Revisiting Invit..
01/10 BioMarin Pharmaceutical (BMRN) presents at 35th Annual J.P. Morgan Healthcare..
01/09 BioMarin Pharma - Orphan Pharma Model Does Not Warrant Special Valuation
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 114 $
Spread / Average Target 32%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..4.00%14 817
BIOGEN INC-1.14%60 997
CSL LIMITED-1.28%38 132
ALEXION PHARMACEUTICAL..9.81%30 085
GRIFOLS SA1.59%13 388
CHONGQING ZHIFEI BIOLO..--.--%3 253
More Results